Cargando…

Bridging intravenous thrombolysis in patients with atrial fibrillation

BACKGROUND AND PURPOSE: 40% of acute ischemic stroke patients treated by mechanical thrombectomy (MT) have a clinical history of atrial fibrillation (AF). The safety of bridging intravenous thrombolysis (IVT) (MT + IVT) is currently being discussed. We aimed to analyze the interaction between oral a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mujanovic, Adnan, Kurmann, Christoph C., Dobrocky, Tomas, Olivé-Gadea, Marta, Maegerlein, Christian, Pierot, Laurent, Mendes Pereira, Vitor, Costalat, Vincent, Psychogios, Marios, Michel, Patrik, Beyeler, Morin, Piechowiak, Eike I., Seiffge, David J., Mordasini, Pasquale, Arnold, Marcel, Gralla, Jan, Fischer, Urs, Kaesmacher, Johannes, Meinel, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382124/
https://www.ncbi.nlm.nih.gov/pubmed/35989924
http://dx.doi.org/10.3389/fneur.2022.945338
_version_ 1784769232480763904
author Mujanovic, Adnan
Kurmann, Christoph C.
Dobrocky, Tomas
Olivé-Gadea, Marta
Maegerlein, Christian
Pierot, Laurent
Mendes Pereira, Vitor
Costalat, Vincent
Psychogios, Marios
Michel, Patrik
Beyeler, Morin
Piechowiak, Eike I.
Seiffge, David J.
Mordasini, Pasquale
Arnold, Marcel
Gralla, Jan
Fischer, Urs
Kaesmacher, Johannes
Meinel, Thomas R.
author_facet Mujanovic, Adnan
Kurmann, Christoph C.
Dobrocky, Tomas
Olivé-Gadea, Marta
Maegerlein, Christian
Pierot, Laurent
Mendes Pereira, Vitor
Costalat, Vincent
Psychogios, Marios
Michel, Patrik
Beyeler, Morin
Piechowiak, Eike I.
Seiffge, David J.
Mordasini, Pasquale
Arnold, Marcel
Gralla, Jan
Fischer, Urs
Kaesmacher, Johannes
Meinel, Thomas R.
author_sort Mujanovic, Adnan
collection PubMed
description BACKGROUND AND PURPOSE: 40% of acute ischemic stroke patients treated by mechanical thrombectomy (MT) have a clinical history of atrial fibrillation (AF). The safety of bridging intravenous thrombolysis (IVT) (MT + IVT) is currently being discussed. We aimed to analyze the interaction between oral anticoagulation (OAC) status or AF with bridging IVT, regarding the occurrence of symptomatic intracranial hemorrhage (sICH) and functional outcome. MATERIALS AND METHODS: Multicentric observational cohort study (BEYOND-SWIFT registry) of consecutive patients undergoing MT between 2010 and 2018 (n = 2,941). Multinomial regression models were adjusted for prespecified baseline and plausible pathophysiological covariates identified on a univariate analysis to assess the association of AF and OAC status with sICH and good outcomes (90-day modified Rankin Scale score 0–2). RESULTS: In the total cohort (median age 74, 50.6% women), 1,347 (45.8%) patients had AF. Higher admission National Institutes of Health Stroke Scale (NIHSS) score (aOR 1.04 [95% 1.02–1.06], per point of increase) and prior medication with Vitamin K antagonists (VKA) (aOR 2.19 [95% 1.27–3.66]) were associated with sICH. Neither AF itself (aOR 0.71 [95% 0.41–1.24]) nor bridging IVT (aOR 1.08 [0.67–1.75]) were significantly associated with increased sICH. Receiving bridging IVT (aOR 1.61 [95% 1.24–2.11]) was associated with good 90-day outcome, with no interaction between AF and IVT (p = 0.92). CONCLUSION: Bridging IVT appears to be a reasonable clinical option in selected patients with AF. Given the increased sICH risk in patients with VKA, subgroup analysis of the randomized controlled trials should analyze whether patients with VKA might benefit from withholding bridging IVT. REGISTRATION: clinicaltrials.gov; Unique identifier: NCT03496064.
format Online
Article
Text
id pubmed-9382124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93821242022-08-18 Bridging intravenous thrombolysis in patients with atrial fibrillation Mujanovic, Adnan Kurmann, Christoph C. Dobrocky, Tomas Olivé-Gadea, Marta Maegerlein, Christian Pierot, Laurent Mendes Pereira, Vitor Costalat, Vincent Psychogios, Marios Michel, Patrik Beyeler, Morin Piechowiak, Eike I. Seiffge, David J. Mordasini, Pasquale Arnold, Marcel Gralla, Jan Fischer, Urs Kaesmacher, Johannes Meinel, Thomas R. Front Neurol Neurology BACKGROUND AND PURPOSE: 40% of acute ischemic stroke patients treated by mechanical thrombectomy (MT) have a clinical history of atrial fibrillation (AF). The safety of bridging intravenous thrombolysis (IVT) (MT + IVT) is currently being discussed. We aimed to analyze the interaction between oral anticoagulation (OAC) status or AF with bridging IVT, regarding the occurrence of symptomatic intracranial hemorrhage (sICH) and functional outcome. MATERIALS AND METHODS: Multicentric observational cohort study (BEYOND-SWIFT registry) of consecutive patients undergoing MT between 2010 and 2018 (n = 2,941). Multinomial regression models were adjusted for prespecified baseline and plausible pathophysiological covariates identified on a univariate analysis to assess the association of AF and OAC status with sICH and good outcomes (90-day modified Rankin Scale score 0–2). RESULTS: In the total cohort (median age 74, 50.6% women), 1,347 (45.8%) patients had AF. Higher admission National Institutes of Health Stroke Scale (NIHSS) score (aOR 1.04 [95% 1.02–1.06], per point of increase) and prior medication with Vitamin K antagonists (VKA) (aOR 2.19 [95% 1.27–3.66]) were associated with sICH. Neither AF itself (aOR 0.71 [95% 0.41–1.24]) nor bridging IVT (aOR 1.08 [0.67–1.75]) were significantly associated with increased sICH. Receiving bridging IVT (aOR 1.61 [95% 1.24–2.11]) was associated with good 90-day outcome, with no interaction between AF and IVT (p = 0.92). CONCLUSION: Bridging IVT appears to be a reasonable clinical option in selected patients with AF. Given the increased sICH risk in patients with VKA, subgroup analysis of the randomized controlled trials should analyze whether patients with VKA might benefit from withholding bridging IVT. REGISTRATION: clinicaltrials.gov; Unique identifier: NCT03496064. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382124/ /pubmed/35989924 http://dx.doi.org/10.3389/fneur.2022.945338 Text en Copyright © 2022 Mujanovic, Kurmann, Dobrocky, Olivé-Gadea, Maegerlein, Pierot, Mendes Pereira, Costalat, Psychogios, Michel, Beyeler, Piechowiak, Seiffge, Mordasini, Arnold, Gralla, Fischer, Kaesmacher, Meinel and the BEYOND-SWIFT Investigators. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Mujanovic, Adnan
Kurmann, Christoph C.
Dobrocky, Tomas
Olivé-Gadea, Marta
Maegerlein, Christian
Pierot, Laurent
Mendes Pereira, Vitor
Costalat, Vincent
Psychogios, Marios
Michel, Patrik
Beyeler, Morin
Piechowiak, Eike I.
Seiffge, David J.
Mordasini, Pasquale
Arnold, Marcel
Gralla, Jan
Fischer, Urs
Kaesmacher, Johannes
Meinel, Thomas R.
Bridging intravenous thrombolysis in patients with atrial fibrillation
title Bridging intravenous thrombolysis in patients with atrial fibrillation
title_full Bridging intravenous thrombolysis in patients with atrial fibrillation
title_fullStr Bridging intravenous thrombolysis in patients with atrial fibrillation
title_full_unstemmed Bridging intravenous thrombolysis in patients with atrial fibrillation
title_short Bridging intravenous thrombolysis in patients with atrial fibrillation
title_sort bridging intravenous thrombolysis in patients with atrial fibrillation
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382124/
https://www.ncbi.nlm.nih.gov/pubmed/35989924
http://dx.doi.org/10.3389/fneur.2022.945338
work_keys_str_mv AT mujanovicadnan bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT kurmannchristophc bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT dobrockytomas bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT olivegadeamarta bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT maegerleinchristian bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT pierotlaurent bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT mendespereiravitor bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT costalatvincent bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT psychogiosmarios bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT michelpatrik bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT beyelermorin bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT piechowiakeikei bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT seiffgedavidj bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT mordasinipasquale bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT arnoldmarcel bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT grallajan bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT fischerurs bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT kaesmacherjohannes bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT meinelthomasr bridgingintravenousthrombolysisinpatientswithatrialfibrillation
AT bridgingintravenousthrombolysisinpatientswithatrialfibrillation